Volume 28, Issue 1 (1-2024)                   IBJ 2024, 28(1): 53-58 | Back to browse issues page

PMID: 38445462
Ethics code: sbmul.REC1394.112


XML Print


Abstract:  
Background: MiR-34a and miR-126 mainly act as tumor suppressors and are often downregulated in various cancers, including non-small cell lung cancer (NSCLC). We aimed to determine the methylation status of miR-34a and miR-126 in NSCLC patients.
Methods: The current study included 63 paraffin-embedded NSCLC and paired adjacent normal tissues. After DNA extraction and bisulfite treatment, the methylation status of miR-34a and miR-126 were evaluated using the MSP method.
Results: There was no statistically significant difference between tumor and normal tissues regarding the methylation status of miR-34a and miR-126
(p > 0.05). Moreover, we found no significant correlation between the methylation status of miR-34a and miR-126 with patients’ demographic parameters, including gender, age, and pathology subtype (p > 0.05).

Conclusion: Considering the low expression of mir-126 and mir-34 in NSCLC, more sensitive methods are recommended to be exploited for detecting the level of methylation or underlying mechanisms other than promoter hypermethylation in silencing these genes in NSCLC.

References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209-49. [DOI:10.3322/caac.21660]
2. Sussan TE, Pletcher MT, Murakami Y, Reeves RH. Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression. Mol Cancer. 2005; 4:28. [DOI:10.1186/1476-4598-4-28]
3. Li ZH, Weng X, Xiong QY, Tu JH, Xiao A, Qiu W, et al. miR-34a expression in human breast cancer is associated with drug resistance. Oncotarget. 2017; 8(63):106270-82. [DOI:10.18632/oncotarget.22286]
4. Kalfert D, Ludvikova M, Pesta M, Ludvik J, Dostalova L, Kholová I. Multifunctional roles of miR-34a in cancer: a review with the emphasis on head and neck squamous cell carcinoma and thyroid cancer with clinical implications. Diagnostics(Basel). 2020; 10(8):563. [DOI:10.3390/diagnostics10080563]
5. Li X, Ren Z, Tang J. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis. 2014; 5(7):e1327. [DOI:10.1038/cddis.2014.270]
6. Garofalo M, Jeon YJ, Nuovo GJ, Middleton J, Secchiero P, Joshi P, et al. MiR-34a/c-dependent PDGFR-α/β downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer. Plos One. 2013; 8(6):e67581. [DOI:10.1371/journal.pone.0067581]
7. Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019; 38(1):53. [DOI:10.1186/s13046-019-1059-5]
8. Kwon H, Song K, Han C, Zhang J, Lu L, Chen W, et al. Epigenetic silencing of miRNA-34a in human cholangiocarcinoma via EZH2 and DNA methylation: impact on regulation of notch pathway. Am J Pathol. 2017; 187(10):2288-99. [DOI:10.1016/j.ajpath.2017.06.014]
9. Cohen Y, Merhavi Shoham E, Avraham RB, Frenkel S, Pe'er J, Goldenberg Cohen N. Hypermethylation of CpG island loci of multiple tumor suppressor genes in retinoblastoma. Exp Eye Res. 2008; 86(2):201-6. [DOI:10.1016/j.exer.2007.10.010]
10. Saito Y, Nakaoka T, Saito H. microRNA-34a as a therapeutic agent against human cancer. J Clin Med. 2015; 4(11):1951-9. [DOI:10.3390/jcm4111951]
11. Rouigari M, Dehbashi M, Ghaedi K, Pourhossein M. Targetome analysis revealed involvement of miR-126 in neurotrophin signaling pathway: a possible role in prevention of glioma development. Cell J. 2018; 20(2):150-6.
12. Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. Plos One. 2016; 11(4):e0153046. [DOI:10.1371/journal.pone.0153046]
13. Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep. 2013; 30(4):1976-84. [DOI:10.3892/or.2013.2633]
14. Zhang Z, Wang J, Cheng J, Yu X. Effects of miR-126 on the STAT3 signaling pathway and the regulation of malignant behavior in lung cancer cells. Oncol Lett. 2018; 15(6):8412-6. [DOI:10.3892/ol.2018.8360]
15. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A. 2008; 105(40):15535-40. [DOI:10.1073/pnas.0808266105]
16. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 2013; 15(3):284-94. [DOI:10.1038/ncb2690]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.